In just 10 years, Amicus Therapeutics has risen to the forefront of the biotechnology industry with a fresh approach to the treatment of genetic disorders and illnesses. The company’s own website boasts a wide range of drug therapies designed to treat a spectrum of rare genetic disorders.
Among the company’s greatest achievements, Amicus Therapeutics has recently unveiled a treatment for Fabry disease, a rare genetic disorder named for Johannes Fabry. The new course of treatments will be also be used to treat Pompe disease and other Lysosomal Storage Disorders through enzyme replacement therapy.
Developing a treatment plan for Lysosomal Storage Disorders is a tremendous advance, but it’s also the kind of thing this growing biotechnology company hopes to do regularly. Since its 2007 inception, Amicus Therapeutics has pledged to deliver the best possible treatments for people living with genetic diseases.
To maintain a vigilant focus on that directive, Amicus Therapeutics keeps a close eye on the community of families affected by rare and orphan genetic illnesses, providing them with support and offering new treatments, as they become available. In that vain, the biotechnology company is keeping an ear to the ground, looking for innovative ways to adapt new technologies and to outperform their own advances.
While Amicus Therapeutics’ own mission statement reveals a thirst for rapid advancement, the company is only limited by a desire for safety in their research and testing phases.
A code of conduct guides Amicus Therapeutics in all areas, from research and development to corporate decision making policies. A message from Patrik Florencio, Amicus Chief Compliance and Risk Officer, emphasizes that care for ethical actions on behalf of the company, ensuring that a concern for their patients won’t forsake greater concerns for the environments in which Amicus Therapeutics operates.
Speaking of their patients, Amicus Therapeutics takes their devotion to their patients into account, when considering new treatments. In searching for new treatments, Amicus collects research that will lead them toward more effective treatments for current and future patients. Incorporating patient input into developing each new therapy, Amicus Therapeutics remains at the forefront of the biotechnology industry .
Visit Amicus Therapeutics on Twitter or see job opportunities at Indeed
Jose Henrique Borghi’s profile as a specialist in advertisement includes high profile clients including Fiat, Unilever, Procter and Mitsubishi. The advertisements he has created for these large corporations have enjoyed international critical acclaim and have won several awards. As the creative mind behind some of the breathtaking advertisements in the world, Mr. Borghi has been honored with dozens of awards from numerous organizations. He has been awarded seven London statutes, fifteen April awards and a further eleven New York Film Festival awards. He has also won 14 Cannes Festival Lions awards to add to his glittering list of awards won, which also includes multiple Clio awards. His trademark creative advertisements such as the stuffed animals campaign he did for Parmalat have punchy messages and images, which leave a lasting impression on the viewers. His creativity has seen him rise through the industry ranks as a little known editor into a global force with international recognition and client base.
Education and Entrepreneurial Endeavors
Jose Henrique Borghi has a solid academic background in advertising having studied Advertising and Propaganda at the prestigious Pontifical Catholic University (PUC). This earned his first job in the industry as an editor at an advertising agency, Standart Ogilvy. From his first job in 1989, Mr. Borghi never looked and set out to make a name for himself not only as an employee but also as an entrepreneur. After leaving Standart Ogilvy, Jose Henrique Borghi worked for several companies including Leo Burnett, Talent and FCB among others. Having gained excellent industry knowledge, he ventured into entrepreneurship by co-founding an advertising agency, BorghiErh Creative Intelligence. He was a co-chief executive officer of the company, which he guided to financial success. The company later merged with Lowe and the resulting agency further merged with Mullen to form Mullen Lowe Brazil. He is currently serving as the chief creativity director and co-chief executive officer of the company.
Good advertising is the nerve of successful businesses. Advertising enables the business to reach more customers and expand. However for this to happen, one needs to find a good advertising agency or person who can develop captivating adverts that can attract prospective customers while retaining the current clientele. In Brazilian advertising, the key to good advertising lies with Jose Henrique Borghi, the co-CEO, and CCO of Mullen Lowe Brasil.
Jose Henrique Borghi is a veteran and popular advertising professional based in Sao Paulo, Brazil. He is a very creative person who has helped many businesses achieve their performance goals through advertising by developing and distributing effective advertising campaigns. José was born in Presidente Prudente.
His first job was at Standart Ogilvy in 1989. He has also worked in other prominent advertising agencies such as FCB, Talent, Leo Burnett and DM9DDB. While working at DM9DDB between 1994 and 1999, he created strong campaigns such as the Mammals of Parmalat and Carlinos. In 1999 he started working at Leo Burnnet as the Chief Creative Officer and later as CEO in 2001. While there, he developed successful campaigns such as Fiat.
In 2002 with Erh Ray they founded their own agency BhorgiErh from scratch. The popular advertising professional based later merged with Lowe and Partners changing the name to Borghi Lowe. Later in 2015, the agency merged with Mullen US becoming Mullen Lowe Group. Its Brazil was named Mullen Lowe Brazil, and Jose Henrique Borghi became its co-CEO and CCO.
About Mullen Lowe Brazil
Mullen Lowe Brazil is part of a larger, Mullen Lowe Group. It is a big advertising agency based in Sao Paulo. It came into existence after the merger of Borghi Lowe and Mullen US in 2015 forming Mullen Lowe Group, and the Brazilian branch was named Mullen Lowe Brazil.
The agency’s specialties are advertising, media, activation, planning, and development of digital content. The company has won many esteemed prizes in Brazil due to its good work in creating publicity. Such prizes include The Colunistas Award which is the oldest and most esteemed prize in Brazil.